Duvic Madeleine
Division of Internal Medicine, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dermatol Clin. 2015 Oct;33(4):757-64. doi: 10.1016/j.det.2015.05.010. Epub 2015 Aug 29.
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's T-cell lymphomas that present as skin lesions. Mycosis fungoides with large cell transformation has a 5-year overall survival of 32% with involved skin and 7% with extracutaneous involvement. Failure to cure advanced MF with large cell transformation and peripheral T-cell lymphoma has resulted in a search for novel targeted agents including antibodies and gene modulators. Histone deacetylase inhibitors are small molecules that seem to be particularly active for T-cell lymphoma.
皮肤T细胞淋巴瘤（CTCLs）是非霍奇金T细胞淋巴瘤，表现为皮肤病变。蕈样肉芽肿伴大细胞转化患者，皮肤受累时5年总生存率为32%，皮肤外受累时为7%。无法治愈晚期伴大细胞转化的蕈样肉芽肿和外周T细胞淋巴瘤，促使人们寻找包括抗体和基因调节剂在内的新型靶向药物。组蛋白去乙酰化酶抑制剂是小分子，似乎对T细胞淋巴瘤特别有效。
